ARCH PATHOL LAB MED:患者-病理学家会诊项目:对癌症患者的兴趣和动机的混合方法研究

2020-05-21 MedSci原创 MedSci原创

病人和做出诊断的病理学家之间有很大障碍和沟通缺乏。最近一些文献表明,在一些成功的项目,患者与病理学家会面,一起回顾他们的病理报告,并在显微镜下观察他们的组织。

病人和做出诊断的病理学家之间有很大障碍和沟通缺乏。最近一些文献表明,在一些成功的项目,患者与病理学家会面,一起回顾他们的病理报告,并在显微镜下观察他们的组织。目前,有多少病人对这样的服务感兴趣,以及什么会驱使感兴趣的病人想要见他们的病理学家,以及它可能提供的具体价值。因此,本研究的目的就是量化病人对病人病理咨询项目的兴趣,定性评估病人兴趣或不兴趣的动机。

从学术癌症中心和当地社区癌症支持小组中招募受试者,以回应一项关于他们对患者-病理学家咨询项目兴趣的调查。同步使用在线表格和纸质调查,通过社交媒体进行推广这项在线调查。

研究结果表明病人的兴趣较高,75%的受访者表示,他们支持“有兴趣的病人-病理学家咨询计划”。感兴趣的关键主题是增强对诊断和疾病的理解,有机会揭开诊断过程的神秘面纱,以及认识到额外的知识将增强患者的能力。

研究结果表明,在选定的一组癌症患者中,患者-病理学家咨询计划的兴趣较高。病理学家、临床医生和医院领导应该共同努力,在不同的环境中试点这些项目。此外,需要进行更多的定量工作来衡量对感兴趣人群的干预措施,需要进行定性工作来设计有效的、以病人为中心的咨询方案并评估其价值。

原始出处:

Cathryn J. Lapedis, MD, MPH; Jennifer K. Horowitz, MA; The Patient-Pathologist Consultation Program: A Mixed-Methods Study of Interest and Motivations in Cancer Patients

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1706725, encodeId=73a31e06725a0, content=<a href='/topic/show?id=c7fd2582e4b' target=_blank style='color:#2F92EE;'>#会诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25827, encryptionId=c7fd2582e4b, topicName=会诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39df31305194, createdName=1249859em48(暂无昵称), createdTime=Wed Dec 02 16:59:06 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786335, encodeId=bf4a1e8633540, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Mar 25 11:59:06 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289678, encodeId=9da012896e877, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473496, encodeId=ad3514e3496ff, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610492, encodeId=5f8a161049270, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1706725, encodeId=73a31e06725a0, content=<a href='/topic/show?id=c7fd2582e4b' target=_blank style='color:#2F92EE;'>#会诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25827, encryptionId=c7fd2582e4b, topicName=会诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39df31305194, createdName=1249859em48(暂无昵称), createdTime=Wed Dec 02 16:59:06 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786335, encodeId=bf4a1e8633540, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Mar 25 11:59:06 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289678, encodeId=9da012896e877, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473496, encodeId=ad3514e3496ff, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610492, encodeId=5f8a161049270, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=)]
    2021-03-25 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1706725, encodeId=73a31e06725a0, content=<a href='/topic/show?id=c7fd2582e4b' target=_blank style='color:#2F92EE;'>#会诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25827, encryptionId=c7fd2582e4b, topicName=会诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39df31305194, createdName=1249859em48(暂无昵称), createdTime=Wed Dec 02 16:59:06 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786335, encodeId=bf4a1e8633540, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Mar 25 11:59:06 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289678, encodeId=9da012896e877, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473496, encodeId=ad3514e3496ff, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610492, encodeId=5f8a161049270, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1706725, encodeId=73a31e06725a0, content=<a href='/topic/show?id=c7fd2582e4b' target=_blank style='color:#2F92EE;'>#会诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25827, encryptionId=c7fd2582e4b, topicName=会诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39df31305194, createdName=1249859em48(暂无昵称), createdTime=Wed Dec 02 16:59:06 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786335, encodeId=bf4a1e8633540, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Mar 25 11:59:06 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289678, encodeId=9da012896e877, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473496, encodeId=ad3514e3496ff, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610492, encodeId=5f8a161049270, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=)]
    2020-05-22 jktdtl
  5. [GetPortalCommentsPageByObjectIdResponse(id=1706725, encodeId=73a31e06725a0, content=<a href='/topic/show?id=c7fd2582e4b' target=_blank style='color:#2F92EE;'>#会诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25827, encryptionId=c7fd2582e4b, topicName=会诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39df31305194, createdName=1249859em48(暂无昵称), createdTime=Wed Dec 02 16:59:06 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786335, encodeId=bf4a1e8633540, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Mar 25 11:59:06 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289678, encodeId=9da012896e877, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473496, encodeId=ad3514e3496ff, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610492, encodeId=5f8a161049270, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 22 23:59:06 CST 2020, time=2020-05-22, status=1, ipAttribution=)]
    2020-05-22 智慧医人

相关资讯

NCCN2013:如何改善癌症患者的医患交流?

那些晚期癌症或不可治愈疾病的患者一直面临着生命即将终结带来的精神上的影响,而针对他们的治疗决策也颇为复杂,为了与上述患者更好的交流,临床医生需要掌握一些行之有效的技巧。西雅图华盛顿大学医学院肿瘤科的教授,同时他也兼任该校的副教授Anthony Back医生认为,针对这一问题的现行做法是失败的。 “我们需要找出如何与病人谈话的技巧,并且在做出治疗决策时能够符合他们的意愿,“Back医生在NCCN第

医患交流有助肾病患者理解疾病预后

    美国杜克大学医学院的Jane O. Schell博士在《美国肾病杂志》(Am J Kidney Dis. 2012 Apr;59(4):495-503.)发表文章指出,肾脏科医师和老年患者讨论肾脏病的病程进展有助患者更好地理解疾病预后并做好准备。       老年晚期肾脏病患者往往伴随较高残疾发病率和死亡率。研究旨在发现如果医生和患者就

这术前谈话水平,再“难缠”的患者都服气了!

医生朋友们在术前谈话时,经常说得口干舌燥,患者却仍然一头雾水。没办法,医学术语太高深,患者听不明白是很正常的,但用什么方式能让患者快速明了所做的手术和处理?